Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995
Buy Report Download FREE Resources

Published: December 29, 2022 Report Code: GDHC260PIDR-ST

Select Item

Type 2 Diabetes Market Report Overview

The T2D market size across the 7MM was valued at $2.43 billion in 2021 and will achieve a CAGR of more than 31% during 2021-2031. The diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity, which will drive market growth during the forecast period.

Type 2 Diabetes Market Outlook, 2021-2031 ($ Billion)

Type 2 Diabetes Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Gain More Information on the Type 2 Diabetes Market Forecast

Download a Free Report Sample

The T2D market research covers the 7MM (France, Germany, Italy, Spain, and the UK) and provides a forecast model for the T2D market through 2031.

Market Size (2021) $2.43 billion
CAGR (2021-2031) >31%
Leading Players ·       Takeda

·       GSK

·       AstraZeneca

·       Novo Nordisk
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Type 2 Diabetes Market Insights

The expiry of established brands, such as Saxenda, leaves these products vulnerable to sales erosion thereby hampering the market growth. However, therapies with new routes of will administration enter the market such as Novo Nordisk’s oral semaglutide (NN-9932), Eli Lilly’s orforglipron, and Pfizer’s PF-07081532 and danuglipron tromethamine, which will propel the market growth in the coming years.

Type 2 Diabetes - Treatment Insights

  • Many of the activities in the developed world promote overindulgence while facilitating sedentary behaviours, leading to an imbalance where there is a juxtaposing surplus in calories consumed and a deficit in calories expended, which is a predisposition to weight gain in the long term. Therefore, as a chronic condition, obesity necessitates timely diagnosis and treatment.
  • Clinical practice favors conservative treatment options relying on behavioral modification for patients with Class I and Class II obesity.
  • Interventional treatment options are offered to patients with obesity. For instance, Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch (BDP/DS), and sleeve gastrectomy collectively comprise the various types of bariatric surgery, a procedure in which stomach size is reduced to limit the amount of food eaten by the individual and decrease nutrient absorption.

Buy the Full Report for More Type 2 Diabetes Treatment Insights

Download a Free Report Sample

Type 2 Diabetes Market - Competitive Landscape

Takeda was the leading sponsor of cell therapy trials in T2D market in 2019.

A few of the leading players in the T2D market are:

  • Takeda
  • GSK
  • AstraZeneca
  • Novo Nordisk

Type 2 Diabetes Market Analysis by Companies

Type 2 Diabetes Market Analysis by Companies

Buy the Full Report for More Type 2 Diabetes Company Insights

Download a Free Report Sample

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM T2D therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM T2D therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Eli Lilly
Novo Nordisk
Sanofi
AstraZeneca
Merck & Co.
Boehringer Ingelheim
GlaxoSmithKline
Takeda
Roche
Pfizer
Johnson & Johnson
Novartis
Theracos
Lexicon Pharmaceuticals
Hua Medicine Shanghai Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd.
Sihuan Pharmaceutical Holdings Group
Biocon Ltd
Oramed Pharamceuticals

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Type 2 Diabetes (T2D): Executive Summary – Updated Dec 2022, based on events up to Dec 5, 2022

1.1 Continued, Significant Growth in the T2D Market, With Drug Sales Expected to Almost Double Across the 9MM by the End of the Forecast Period

1.2 T2D Developers Battle for Share in an Increasingly Crowded Market

1.3 Decrease in Sales Among Branded T2D Drugs Across the 9MM

1.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Reduced Risk of Major Adverse Cardiovascular Events

1.5 Label Expansions for SGLT-2 Inhibitors

1.6 What Do Physicians Think?

2 Introduction – Updated Dec 2022, based on events up to Dec 5, 2022

2.1 Catalyst

2.2 Related Reports

3 Disease Overview

3.1 Etiology

3.2 Pathophysiology

3.3 Symptoms

3.4 Prognosis and Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of T2D

4.4.3 Forecast Assumptions and Methods: Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

4.4.4 Forecast Assumptions and Methods: Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

4.4.5 Forecast Assumptions and Methods: Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

4.4.6 Forecast Assumptions and Methods: Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

4.4.7 Forecast Assumptions and Methods: Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

4.4.8 Forecast Assumptions and Methods: Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D

4.5 Epidemiological Forecast for Type 2 Diabetes (2018–2028)

4.5.1 Diagnosed Prevalent Cases of T2D

4.5.2 Age-Specific Diagnosed Prevalent Cases of T2D

4.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D

4.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 US

5.3 5EU

5.3.1 France

5.3.2 Germany

5.3.3 Italy

5.3.4 Spain

5.3.5 UK

5.4 Japan

5.5 China

5.6 India

6 Competitive Assessment – Updated Dec 2022, based on events up to Dec 5, 2022

6.1 Overview

7 Unmet Needs and Opportunities

7.1 Overview

7.2 Disease-Modifying Treatments Providing Sustained Glycemic Control

7.3 Drugs with Non-glycemic Benefits

7.4 Drugs with Improved Side-Effect Profiles

7.5 Increased Patient Compliance

7.6 Drugs for the Emergent T2D Pediatric Population

7.7 Controls on Insulin Drug Pricing and the Need for Fairly Priced Biologics

8 Pipeline Assessment – Updated Dec 2022, based on events up to Dec 5, 2022

8.1 Overview

8.2 Promising Drugs in Clinical Development

9 Current and Future Players – Updated Dec 2022, based on events up to Dec 5, 2022

9.1 Overview

9.2 Trends in Corporate Strategy

10 Market Outlook – Updated Dec 2022, based on events up to Dec 5, 2022

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers – Global Issues

10.2 US

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 China

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

10.6 India

10.6.1 Forecast

10.6.2 Key Events

10.6.3 Drivers and Barriers

11 Appendix

11.1 Abbreviations

11.2 Bibliography

11.3 Methodology

11.3.1 Forecasting Methodology

11.4 Physicians and Specialists Included in this Study

11.5 About the Authors

11.5.1 Healthcare Analyst

11.5.2 Therapy Area Director

11.5.3 Epidemiologists

11.5.4 Vice President of Disease Analysis and Intelligence

11.5.5 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: T2D: Key Metrics in the Nine Major Pharmaceutical Markets

Table 2: Primary Pathophysiologic Conditions Associated with T2D

Table 3: Symptoms of T2D presents an overview of the most frequently observed symptoms for T2D.

Table 4: Risk Factors and Comorbidities for T2D

Table 5: Diagnostic Tests and Typical Criteria for Diagnosing T2D

Table 6: Country Profile, T2D Management, US

Table 7: Country Profile, T2D Management, France

Table 8: Country Profile, T2D Management, Germany

Table 9: Absence of Typical T2D Symptoms, Italy

Table 10: Individuals with Increased Risk of T2D, Italy

Table 11: Country Profile, T2D Management, Italy

Table 12: Country Profile, T2D Management, Spain

Table 13: Country Profile, T2D Management, UK

Table 14: Country Profile, T2D Management, Japan

Table 15: Country Profile, T2D Management, China

Table 16: Country Profile, T2D Management, India

Table 17: Leading Branded Treatments for T2D, 2022

Table 18: T2D Market – Drivers and Barriers, 2020

Table 19: Key Events Impacting Sales for T2D in the US, 2019–2029

Table 20: T2D Market – Drivers and Barriers in the US, 2020

Table 21: Key Events Impacting Sales for T2D in the 5EU, 2019–2029

Table 22: T2D Market – Drivers and Barriers in the 5EU, 2020

Table 23: Key Events Impacting Sales for T2D in Japan, 2019–2029

Table 24: T2D Market – Drivers and Barriers in Japan, 2020

Table 25: Key Events Impacting Sales for T2D in China, 2019–2029

Table 26: T2D Market – Drivers and Barriers in China, 2020

Table 27: Key Events Impacting Sales for T2D in India, 2019–2029

Table 28: T2D Market – Drivers and Barriers in India, 2020

Table 29: Number of High-Prescribing Physicians Surveyed

Figures

Figure 1: Global Sales By Region (Type 2 Diabetes) 2019 and 2029

Figure 2: Company Portfolio Gap Analysis in T2D, 2019–2029

Figure 3: Competitive Assessment of Late-Stage (Phase III) Pipeline Agents in T2D, 2019–2029

Figure 4: T2D Pathophysiology

Figure 5: 9MM, Diagnosed Prevalence of T2D (%), Men, All Ages, 2018

Figure 6: 9MM, Diagnosed Prevalence of T2D (%), Women, All Ages, 2018

Figure 7: 9MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of T2D

Figure 8: 9MM, Sources Used to Forecast the Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

Figure 9: 9MM, Sources Used to Forecast the Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

Figure 10: 9MM, Sources Used to Forecast the Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

Figure 11: 9MM, Sources Used to Forecast the Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

Figure 12: 9MM, Sources Used to Forecast the Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

Figure 13: 9MM, Sources Used to Forecast the Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D

Figure 14: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 15: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2018

Figure 16: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, All Ages, N, 2018

Figure 17: 9MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 18: 9MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 19: 9MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 20: 9MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 21: 9MM, Diagnosed Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 22: 9MM, Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Figure 23: ADA Treatment Algorithm for Antihyperglycemic Therapy in T2D

Figure 24: Unmet Needs and Opportunities in T2D

Figure 25: Pipeline Agents in Development for T2D

Figure 26: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to be Licensed for T2D in the 9MM During the Forecast Period

Figure 27: Company Portfolio Gap Analysis in T2D, 2019–2029

Figure 28: Global Sales for T2D by Country/Region, 2019 and 2029

Figure 29: Sales for T2D in the US by Drug Class, 2019 and 2029

Figure 30: Sales for T2D in the 5EU by Drug Class, 2019 and 2029

Figure 31: Sales for T2D in Japan by Drug Class, 2019 and 2029

Figure 32: Sales for T2D in China by Drug Class, 2019 and 2029

Figure 33: Sales for T2D in India by Drug Class, 2019 and 2029

Frequently asked questions

Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

Most Popular
$29,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Type 2 Diabetes reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 in real time.

  • Access a live Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more